文献速递神经肿瘤

胶质母细胞瘤趋势:随时间及干预类型变化的结局——一项系统性循证分析

Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.
PubMed 文献 · J Neurooncol · 2020-03-09

该研究按PRISMA指南系统检索1978至2018年新诊断胶质母细胞瘤文献,纳入成人且样本量≥25的全文论文,分析中位总生存随时间和治疗方式的变化。中位总生存集中趋势为13.5个月,累计5年生存率为5.8%;替莫唑胺联合放疗实施后研究的中位生存较实施前显著延长。临床试验中贝伐珠单抗、肿瘤治疗电场和疫苗报告的中位生存集中值最高。

要点

  • 中位总生存集中趋势为13.5个月(范围2.3-29.6),累计5年生存率为5.8%(范围0.01%-29.1%)。
  • 替莫唑胺联合放疗实施后研究的中位生存较实施前显著延长:12.5个月 vs 15.6个月,P<0.001。
  • 临床试验中肿瘤治疗电场报告的中位生存集中值最高,为20.7个月(范围20.5-20.9)。

核心结论

  • 替莫唑胺与放疗联合给药使胶质母细胞瘤患者生存获得统计学显著延长,但该病的自然史仍然很差。
  • 包括肿瘤治疗电场在内的疗法汇总了中位总生存值,并提供了延长胶质母细胞瘤患者生存的手段。

研究设计与样本

  • 按PRISMA指南开展的系统性综述,检索1978年至2018年新诊断胶质母细胞瘤文献。
  • 纳入标准为全文胶质母细胞瘤论文、人类受试者、年龄≥18岁且样本量n≥25。

主要发现

  • 中位总生存的集中趋势为13.5个月(范围2.3-29.6),累计5年生存率为5.8%(范围0.01%-29.1%)。
  • 替莫唑胺和放疗实施前与实施后研究间的生存差异显著:12.5个月(范围2.3-28) vs 15.6个月(范围3.8-29.6),P<0.001。
  • 临床试验中,贝伐珠单抗报告的中位生存集中值为18.2个月(范围10.6-23.0),肿瘤治疗电场为20.7个月(范围20.5-20.9),疫苗为19.2个月(范围15.3-26.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite aggressive treatment with chemoradiotherapy and maximum surgical resection, survival in patients with glioblastoma (GBM) remains poor. Ongoing efforts are aiming to prolong the lifespan of these patients; however, disparities exist in reported survival values with lack of clear evidence that objectively examines GBM survival trends. We aim to describe the current status and advances in the survival of patients with GBM, by analyzing median overall survival through time and between treatment modalities. METHODS: A systematic review was conducted according to PRISMA guidelines to identify articles of newly diagnosed glioblastoma from 1978 to 2018. Full-text glioblastoma papers with human subjects, ≥ 18 years old, and n ≥ 25, were included for evaluation. RESULTS: The central tendency of median overall survival (MOS) was 13.5 months (2.3-29.6) and cumulative 5-year survival was 5.8% (0.01%-29.1%), with a significant difference in survival between studies that predate versus postdate the implementation of temozolomide and radiation, [12.5 (2.3-28) vs 15.6 (3.8-29.6) months, P < 0.001]. In clinical trials, bevacizumab [18.2 (10.6-23.0) months], tumor treating fields (TTF) [20.7 (20.5-20.9) months], and vaccines [19.2 (15.3-26.0) months] reported the highest central measure of median survival. CONCLUSION: Coadministration with radiotherapy and temozolomide provided a statistically significant increase in survival for patients suffering from glioblastoma. However, the natural history for GBM remains poor. Therapies including TTF pooled values of MOS and provide means of prolonging the survival of GBM patients.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, et al. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J Neurooncol. 2020. PMID: 32157552. doi:10.1007/s11060-020-03451-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。